Tissue Genesis, LLC Provides Cell Isolation Processing for Patients with Critical Limb Ischemia (CLI) in Ukrainian Clinical Study

Study to investigate whether adipose-derived SVF therapy can reduce amputation, speed up wound healing and increase ambulatory function.

HOUSTON (March 26, 2019) — Tissue Genesis, LLC, the leading provider of cell isolation technology is pleased to announce that the Icellator® is being used to generate therapeutic cell preparations at the V.P. Komisarenko Institute of Endocrinology and Metabolism in Kiev, Ukraine, for patients with critical limb ischemia (CLI). The autologous stem-cell therapy, which utilizes a patient’s own fat cells, is the first of its kind in Ukraine to treat CLI patients. This effort will build on previous stem cell studies that have shown promising results as a potential therapeutic option for this debilitating and increasingly common vascular disease.

Read more

Tissue Genesis Introduces State-of-the-Art Icellator® X

The enhanced enzyme-derived stem cell isolation system offers a greater overall impact and efficiency in the field of regenerative medicine

Houston (December 11, 2018) – Tissue Genesis LLC announced today the release of the Icellator® X, the newest and most advanced system for isolating stem cells in adipose tissue.

The Icellator® X expands on the capabilities of the original Icellator®, representing a major advancement in the real-world application of stem therapies for patients.

The new-to-market Icellator® X offers greater stem cell yields, improved ease of use, and a user interface available in multiple languages. It is immediately the most efficient system available on the market. The 2019 Icellator® X lets medical professionals and scientists rapidly recover millions of a patient’s own adult stem cells for therapeutic treatments and research applications.

Read more

TG & Human Life CORD, Japan Announce Exclusive Partnership

HOUSTON (Nov. 1, 2017) – Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. Read more